8-KLeadership ChangesOther EventsExhibits & Filings

DEXCOM INC 8-K Report, Executive Changes (Aug 28, 2023)

Filed August 28, 2023For Securities:DXCM

Summary

DexCom, Inc. (DXCM) announced the appointment of Rimma Driscoll to its Board of Directors, effective August 24, 2023. Ms. Driscoll will fill a vacant seat and will also serve on the Audit Committee and the Technology Committee. Her appointment strengthens the board's expertise and governance structure, particularly in areas critical to DexCom's business operations and innovation. She is considered an independent director under Nasdaq listing standards. In connection with her appointment, Ms. Driscoll will receive equity compensation, including an initial retainer grant of restricted stock units (RSUs) valued at $500,000, vesting over three years, and a customary annual RSU grant valued at $325,000, vesting in one year. This compensation aligns with the company's policy for non-employee directors and is intended to incentivize long-term value creation. The company also announced this appointment via a press release, which is furnished as an exhibit to this filing.

Key Highlights

  • 1Rimma Driscoll appointed to DexCom's Board of Directors, effective August 24, 2023.
  • 2Ms. Driscoll will serve on both the Audit Committee and the Technology Committee.
  • 3Her appointment fills a vacancy on the Board and replaces Nicholas Augustinos on the committees.
  • 4Ms. Driscoll has been determined to be an independent director according to Nasdaq listing standards.
  • 5She will receive an initial RSU grant valued at $500,000, vesting over three years.
  • 6A customary annual RSU grant of $325,000 will also be awarded, vesting in one year.
  • 7The appointment was announced via a press release furnished as an exhibit.

Frequently Asked Questions

Rimma Driscoll is a newly appointed independent director to DexCom's Board of Directors. She has been appointed to fill a vacancy and to bring her expertise to the Audit and Technology Committees. Her qualifications meet the independence requirements set by Nasdaq.

Upon her appointment, Ms. Driscoll received an initial retainer grant of restricted stock units (RSUs) valued at $500,000, which will vest annually over three years. She will also receive the standard annual compensation for non-employee directors, which is a $325,000 RSU grant vesting in one year.

No, the filing states that Ms. Driscoll is not a party to and does not have any direct or indirect material interest in any transaction with Dexcom that would require disclosure under SEC regulations.

Her addition to the Audit Committee enhances the oversight of financial reporting and internal controls, while her membership on the Technology Committee strengthens the board's focus on innovation and product development, which are crucial for DexCom's growth in the diabetes technology market.